Leclaza Lazcluze
Named-patient access overview. Leclaza Lazcluze is coordinated by Reserve Meds for international patients through cross-border sourcing coordinated with your treating doctor.
Ask about Leclaza Lazcluze
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
About Leclaza Lazcluze
Leclaza / Lazcluze (lazertinib) is manufactured by Yuhan / J&J and indicated for EGFR+ 1L NSCLC (combo w/ amivantamab). It is a combination of an oral EGFR tyrosine kinase inhibitor and a bispecific antibody approved by the US FDA in 2024 and may be accessible to international patients through Named Patient Program or personal-import pathways.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
How Reserve Meds coordinates Leclaza Lazcluze
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Leclaza Lazcluze for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Leclaza Lazcluze is sourced from a US-licensed pharmaceutical wholesale partner with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
Reserve Meds publishes a detailed country deep-dive for Leclaza Lazcluze in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), how quotes work, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Leclaza Lazcluze
Send us the medicine and your country. We reply within one business day with case-specific feasibility, timeline, and a formal quote.
Frequently asked questions
How can I get Leclaza Lazcluze if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Leclaza Lazcluze for patients through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Leclaza Lazcluze through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Leclaza Lazcluze. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Leclaza Lazcluze through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Leclaza Lazcluze to a patient?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Leclaza Lazcluze to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Leclaza Lazcluze cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Leclaza Lazcluze?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.